Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer

BACKGROUND: A standard of care for pretreated, advanced non–small‐cell lung cancers (NSCLCs), nivolumab has demonstrated long‐term benefit when administered for 2 years. We aimed to better discern an optimized administration duration by retrospectively analyzing real‐life long‐term efficacy in a pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Geier, Margaux, Descourt, Renaud, Corre, Romain, Léveiller, Guillaume, Lamy, Régine, Goarant, Éric, Bizec, Jean‐Louis, Bernier, Cyril, Quéré, Gilles, Amrane, Karim, Gaye, Elisabeth, Lucia, François, Burte, Emilie, Chouaid, Christos, Robinet, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541160/
https://www.ncbi.nlm.nih.gov/pubmed/32412157
http://dx.doi.org/10.1002/cam4.3120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541160/
https://www.ncbi.nlm.nih.gov/pubmed/32412157
http://dx.doi.org/10.1002/cam4.3120

Ejemplares similares